Mayzent is a sphingosine-1-phosphate receptor modulator (S1PR), an immune system-modulating therapy.
Tablet taken orally
Once per day
Relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS
Compared to placebo:
- 55% relative risk reduction in annual relapse rate
- 81% reduction in new or enlarging T2 lesions
- 86% relative risk reduction T1 GD lesions
- 26% relative risk reduction in disability progression
Common Potential Side Effects
Headache, high blood pressure, changes in liver function.
For assistance finding additional resources that might help cover the costs of your prescription, contact MSAA.
HOW Mayzent® WORKS
Mayzent is an immune system-modulating therapy thought to work by trapping lymphocytes (white blood cells) in the lymph nodes to reduce damage to the nerves.
Mayzent was FDA approved in 2019 to treat relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease, in adults.
Potential Side Effects
Headache, high blood pressure, and changes in liver function tests were the most common adverse reactions. Possible serious adverse events include a decrease in white blood cells, heart rate, and rhythm abnormalities, as well as hypertension, macular edema (swelling behind the eye), varicella zoster reactivation (virus that causes shingles), and convulsions.
OTHER KEY INFORMATION
Testing completed prior to starting Mayzent® includes:
- Genotype testing – determines the appropriate dose for the patient
- Complete blood count evaluation
- Liver function test
- Eye exam
- Cardiac evaluation – for preexisting cardiac conduction abnormality
- Test for varicella virus antibody
Annual testing completed after starting Mayzent® includes:
- Consider yearly eye exam
- Consider yearly skin exam
Regular testing completed after starting Mayzent® includes:
- Liver function test
- Complete blood count
- Blood pressure
When starting Mayzent, please note there is a titration period (starting at a smaller dose and increasing over successive weeks).
Patient advocates talk about
their treatment experience
Kristie Salerno Kent“I have had situations where treatments aren’t approved at first. My doctors, nurses, they actually go to bat for me and made it happen.”
Azure Antoinette"I will be undergoing my first disease-modifying therapy to help treat multiple sclerosis in my body and while I’m very nervous, I am equally as excited and looking forward to the positive effects of how I will feel physically, and mentally, and emotionally."
Damian Washington“Nobody’s going to be looking out for your best interests better than you.”
Cathy Chester“I think it’s really important to talk about how to age with this illness.”
Lauren Hutton-Work“Just because you have this disease does not mean that your work life should be awkward or uncomfortable.”
Chernise Joseph“My first neurologist was a frontline neurologist, he wasn’t an MS specialist.”
Julian Gamboa“If you’re newly diagnosed with multiple sclerosis remember it’s always okay to get a second opinion.”
Lauren and Sam Alcorn“Our future is uncertain and we have to enjoy each other and love each other in the present.”
Shawn Feliciano“I want to know what medications might work best for someone who’s Hispanic.”
Darlene Feigen“The sooner you get on a therapy the better it is in the long run.”
Birgit Bauer“At the end of the appointment you should have an answer to the most important questions.”
Ellen Tutton“I looked up all the different disease-modifying therapies and compared them to my lifestyle.”
Victoria Marie Reese“I’m trying to show my daughter that taking care of yourself is cool.”